RxDoctor Payments Data

Alberto Lopez-Silvero, MD

Internal Medicine · Elizabeth, NJNPI 1104901842

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 84 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$239
  • Novo Nordisk$179
  • Sanofi-aventis U.S. LLC$141
  • Lilly USA, LLC$134
  • Amarin Pharma, Inc.$85
  • AstraZeneca$80
  • plus $329 from 11 others

What the payments were for

  • Food & beverage$1,15697%
  • Education$313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,187 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,460
Medicare patients
114
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide199$238,079
FarxigaDapagliflozin Propanediol162$163,617
JanuviaSitagliptin Phosphate108$127,928
JardianceEmpagliflozin67$84,514
TrulicityDulaglutide59$73,975
LinzessLinaclotide53$52,449
ProliaDenosumab29$50,175
OzempicSemaglutide49$46,237
TradjentaLinagliptin40$28,268
Tresiba Flextouch U-200Insulin Degludec16$27,386
EntrestoSacubitril/Valsartan29$23,489
JanumetSitagliptin Phos/Metformin Hcl20$18,324
EliquisApixaban18$15,879
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$15,709
CreonLipase/Protease/Amylase13$14,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$134$312,054258 claims
AstraZenecaFarxiga$80$163,617162 claims
MerckJanuvia, Janumet$40$146,251128 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto$54$134,949136 claims
AbbVieLinzess, Creon$39$66,85366 claims
AmgenProlia$239$50,17529 claims
Novo NordiskOzempic$179$46,23749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →